stockrow
Friday 6 November 2026
Export XWEL’s income statement to Excel — free account
XWELL, Inc.
XWEL Healthcare Diagnostics & Research
XWELL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.2 million, down 13.8% from fiscal 2024.
- Revenue
- −7.08%
- EPS
- +53.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
0.56
0.01
−1.75%
Follow XWEL
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.19 | 0.09 | 0.30 | 0.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.71) | (60.90) | (1.85) | (1.95) | |
P/B ratio |
1.86 | 0.00 | 0.84 | 1.07 | |
Price to Tangible BV |
6.46 | 0.00 | 0.85 | 1.07 | |
EV/Sales |
0.19 | 0.18 | (0.11) | 0.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.21 | 0.00 | |
EV/Operating CF |
(0.45) | (0.59) | 0.34 | (0.20) | |
EV/FCF |
(0.36) | (0.44) | 0.25 | (0.17) | |
Quick Ratio |
0.57 | 0.32 | 2.16 | 2.04 | |
Current Ratio |
1.08 | 0.46 | 2.35 | 2.27 | |
Net Debt/EBITDA |
13.12 | (0.15) | 3.26 | 6.31 | |
Debt/Assets |
0.00% | 32.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | (0.28) | 0.00 | 0.00 | |
Asset Turnover |
1.06 | 1.60 | 1.16 | 1.32 | |
Operating CF/Net income |
1.43 | 0.00 | 0.41 | 2.02 | |
Capex/Depreciation |
(2.11) | (0.28) | (1.52) | (0.72) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.16% | 81.85% | 114.42% | 65.08% | |
Intangible Assets out of Total Assets |
0.10 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.23% | 2.28% | 13.35% | 1.37% | |
Graham Net Nets |
(1.38) | (7.08) | 0.57 | 0.32 | |
Graham Number |
0.00 | 16.27 | 0.00 | 0.00 | |
Earnings Yield |
(340.40%) | (1,110.87%) | (488.70%) | (511.54%) | |
Free Cash Flow Yield |
(265.12%) | (456.56%) | (141.87%) | (152.68%) | |
Revenue per Share |
1.27 | 1.29 | 0.90 | 0.84 | |
Operating CF per Share |
(0.37) | (0.01) | (0.62) | (0.53) | |
Capex per Share |
(0.16) | (0.13) | (0.05) | (0.02) | |
Free Cash Flow per Share |
(0.53) | (0.13) | (0.67) | (0.55) | |
Cash per Share |
0.73 | 0.47 | 2.27 | 1.39 | |
Shareholders Equity per Share |
0.53 | (2.30) | 1.36 | 0.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.53 | (2.30) | 1.36 | 0.97 | |
Free Cash Flow |
(3.05) | (0.75) | (4.99) | (4.68) | |
Working Capital |
0.76 | (6.98) | 11.36 | 8.47 | |
Capital Expenditures |
(0.94) | (0.71) | (0.39) | (0.17) | |
Net Current Asset Value |
(7.86) | (18.11) | 4.83 | 2.87 | |
EV/EBIT |
0.00 | 0.00 | 0.17 | 0.00 | |
Capex to Sales |
0.13 | 0.10 | 0.06 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.20 | 1.68 | 1.41 | 1.65 | |
Average Payables |
2.92 | 2.22 | 2.87 | 1.74 | |
Average Inventory |
0.59 | 0.51 | 0.49 | 0.48 | |
Average Assets |
27.76 | 18.28 | 24.91 | 21.49 | |
Average Common Equity |
8.95 | (2.53) | 6.47 | 5.98 |
Columns are period end dates · fundamentals updated 25 Oct 2026